News | November 13, 2024
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Silica is a proven and highly effective anti-caking agent that has been used for decades
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
This initiative aims to raise awareness about the importance of monitoring blood sugar levels before indulging in sweets
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Subscribe To Our Newsletter & Stay Updated
